Psoriasis is one of the most common skin diseases. According to various studies, 1—3% of the population suffer from this disease regardless of gender, race, and geographic location. Treatment of psoriasis is one of the most challenging therapeutic problems. The aim of this study was to investigate the effectiveness of complex treatment regimen for extensive psoriasis vulgaris, which includes polycomponent hepatoprotector Remaxol. The data of 95 patients diagnosed with advanced stage of extensive psoriasis vulgaris, who were treated at the advisory out-patient clinic and hospital of the Rostov State Medical University. Depending on the regimen, patients were divided into two groups: study group patients (n=53), along with basic therapy, were administered with once-daily intravenous Remaxol at a dose of 400,0 ml on every other day for 14 days; control group patients (n=42) received a conventional basic treatment. It was found that the complex treatment regimen including Remaxol demonstrated higher efficacy in treatment of advanced stages of extensive psoriasis vulgaris as evidenced by faster relief of clinical manifestations of a specific process, and, as a consequence, decrease in average PASI index by 74.4% compared to 46.7% in patients who received standard treatment. Hepatoprotective effect of the drug was evident as significant decrease in transaminase levels that were initially elevated, reduction and normalization of alkaline phosphatase and cholesterol levels, reduction of high levels of bilirubin and its fractions, and significant decrease in leukocyte index of intoxication.